Dexcel Pharma Technologies Ltd. - Net Worth and Insider Trading

Dexcel Pharma Technologies Ltd. Net Worth

The estimated net worth of Dexcel Pharma Technologies Ltd. is at least $1.3 Billion dollars as of 2024-12-01. Dexcel Pharma Technologies Ltd. is the 10% Owner of Roivant Sciences Ltd and owns about 102,849,443 shares of Roivant Sciences Ltd (ROIV) stock worth over $1.3 Billion. Dexcel Pharma Technologies Ltd. is the 10% Owner of Protalix BioTherapeutics Inc and owns about 3,637,314 shares of Protalix BioTherapeutics Inc (PLX) stock worth over $6 Million. Dexcel Pharma Technologies Ltd. is also the 10% Owner of Intec Parent Inc and owns about 52,936 shares of Intec Parent Inc (NTEC) stock worth over $509,774. Details can be seen in Dexcel Pharma Technologies Ltd.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Dexcel Pharma Technologies Ltd. has not made any transactions after 2022-11-10 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Dexcel Pharma Technologies Ltd.

To

Dexcel Pharma Technologies Ltd. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Dexcel Pharma Technologies Ltd. owns 7 companies in total, including Intec Parent Inc (NTEC) , Arbutus Biopharma Corp (ABUS) , and Sio Gene Therapies Inc (SIOX) among others .

Click here to see the complete history of Dexcel Pharma Technologies Ltd.’s form 4 insider trades.

Insider Ownership Summary of Dexcel Pharma Technologies Ltd.

Ticker Comapny Transaction Date Type of Owner
NTEC Intec Parent Inc 2020-02-04 10 percent owner
ABUS Arbutus Biopharma Corp 2017-09-06 10 percent owner
SIOX Sio Gene Therapies Inc 2017-09-06 10 percent owner
LIMIT LIMIT 2017-09-06 10 percent owner
LIMIT LIMIT 2019-07-10 other: See remarks
LIMIT LIMIT 2021-06-03 10 percent owner
LIMIT LIMIT 2022-11-10 10 percent owner

Dexcel Pharma Technologies Ltd. Latest Holdings Summary

Dexcel Pharma Technologies Ltd. currently owns a total of 3 stocks. Among these stocks, Dexcel Pharma Technologies Ltd. owns 102,849,443 shares of Roivant Sciences Ltd (ROIV) as of November 10, 2022, with a value of $1.3 Billion and a weighting of 99.49%. Dexcel Pharma Technologies Ltd. owns 3,637,314 shares of Protalix BioTherapeutics Inc (PLX) as of June 3, 2021, with a value of $6 Million and a weighting of 0.48%. Dexcel Pharma Technologies Ltd. also owns 52,936 shares of Intec Parent Inc (NTEC) as of February 4, 2020, with a value of $509,774 and a weighting of 0.04%.

Latest Holdings of Dexcel Pharma Technologies Ltd.

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ROIV Roivant Sciences Ltd 2022-11-10 102,849,443 12.71 1,307,216,421
PLX Protalix BioTherapeutics Inc 2021-06-03 3,637,314 1.72 6,256,180
NTEC Intec Parent Inc 2020-02-04 52,936 9.63 509,774

Holding Weightings of Dexcel Pharma Technologies Ltd.


Dexcel Pharma Technologies Ltd. Form 4 Trading Tracker

According to the SEC Form 4 filings, Dexcel Pharma Technologies Ltd. has made a total of 2 transactions in Roivant Sciences Ltd (ROIV) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in Roivant Sciences Ltd is the acquisition of 4,000,000 shares on November 10, 2022, which cost Dexcel Pharma Technologies Ltd. around $20 Million.

According to the SEC Form 4 filings, Dexcel Pharma Technologies Ltd. has made a total of 1 transactions in Protalix BioTherapeutics Inc (PLX) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Protalix BioTherapeutics Inc is the sale of 918,717 shares on June 3, 2021, which brought Dexcel Pharma Technologies Ltd. around $2 Million.

According to the SEC Form 4 filings, Dexcel Pharma Technologies Ltd. has made a total of 1 transactions in Intec Parent Inc (NTEC) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Intec Parent Inc is the sale of 11,449 shares on February 4, 2020, which brought Dexcel Pharma Technologies Ltd. around $283,945.

Insider Trading History of Dexcel Pharma Technologies Ltd.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Dexcel Pharma Technologies Ltd. Trading Performance

GuruFocus tracks the stock performance after each of Dexcel Pharma Technologies Ltd.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Dexcel Pharma Technologies Ltd. is 28.29%. GuruFocus also compares Dexcel Pharma Technologies Ltd.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Dexcel Pharma Technologies Ltd. within 3 months outperforms 2 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Dexcel Pharma Technologies Ltd.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Dexcel Pharma Technologies Ltd.

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
2 out of 2 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 16.34 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 20.31 LIMIT LIMIT LIMIT LIMIT LIMIT

Dexcel Pharma Technologies Ltd. Ownership Network

Ownership Network List of Dexcel Pharma Technologies Ltd.

No Data

Ownership Network Relation of Dexcel Pharma Technologies Ltd.

Insider Network Chart

Dexcel Pharma Technologies Ltd. Owned Company Details

What does Intec Parent Inc do?

Who are the key executives at Intec Parent Inc?

Dexcel Pharma Technologies Ltd. is the 10 percent owner of Intec Parent Inc. Other key executives at Intec Parent Inc include Chief Business Officer Walt Addison Linscott , Chief Financial Officer Nir Sassi , and Chief Operating Officer Nadav Navon .

Intec Parent Inc (NTEC) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Intec Parent Inc (NTEC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Intec Parent Inc (NTEC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Intec Parent Inc (NTEC)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Intec Parent Inc Insider Transactions

No Available Data

Dexcel Pharma Technologies Ltd. Mailing Address

Above is the net worth, insider trading, and ownership report for Dexcel Pharma Technologies Ltd.. You might contact Dexcel Pharma Technologies Ltd. via mailing address: 1 Dexcel Street, Or Akiva L3 3060000.

Discussions on Dexcel Pharma Technologies Ltd.

No discussions yet.